Comprehensive precision medicine strategies require a comprehensive multidisciplinary approach.

Screening assays must be sufficiently broad to identify the full landscape of actionable genomic alterations.

Profiling must be applied broadly, irrespective of whether molecular testing is required to guide standard-of-care therapy.

Multi-histology biomarker-selected ‘basket’ studies support treatment based on identified actionable alterations.